NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada

NCT02552849

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: No intervention

Countries: Canada

This is a multi-center, non-interventional study to assess and describe course and outcomes in patients diagnosed with Idiopathic Pulmonary Fibrosis (IPF) who are treated with Esbriet (pirfenidone) in Canada, by measuring and reporting observed predicted forced vital capacity (FVC) change from baseline on an ongoing basis.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* \> or = 18 years of age
* Diagnosis of Idiopathic Pulmonary Fibrosis (IPF)
* Prescribed and/or currently taking Esbriet (pirfenidone) for the treatment of IPF

Exclusion Criteria:

* Hypersensitivity to Esbriet (pirfenidone)
* Concomitant use of fluvoxamine
* Severe hepatic impairment or end-stage liver disease
* Severe renal impairment or end-stage renal disease requiring dialysis

Locations (26)

Calgary, Alberta, Canada
Edmonton, Alberta, Canada
Edmonton, Alberta, Canada
Sherwood Park, Alberta, Canada
Kelowna, British Columbia, Canada
North Vancouver, British Columbia, Canada
Vancouver, British Columbia, Canada
Vancouver, British Columbia, Canada
Winnipeg, Manitoba, Canada
Moncton, New Brunswick, Canada
Saint John, New Brunswick, Canada
St. John's, Newfoundland and Labrador, Canada
St. John's, Newfoundland and Labrador, Canada
Burlington, Ontario, Canada
Hamilton, Ontario, Canada
Kingston, Ontario, Canada
London, Ontario, Canada
Mississauga, Ontario, Canada
Oshawa, Ontario, Canada
Ottawa, Ontario, Canada
Owen Sound, Ontario, Canada
Toronto, Ontario, Canada
Windsor, Ontario, Canada
Windsor, Ontario, Canada
Montreal, Quebec, Canada
Saint-Charles-Borromée, Quebec, Canada